HC Wainwright & Co. Reiterates Buy on Cadrenal Therapeutics, Maintains $3 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating on Cadrenal Therapeutics (NASDAQ:CVKD) and maintained a $3 price target.
May 09, 2024 | 3:29 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cadrenal Therapeutics maintains a Buy rating and a $3 price target from HC Wainwright & Co.
The reiteration of a Buy rating and maintenance of a $3 price target by a reputable analyst firm like HC Wainwright & Co. typically signals continued confidence in the company's prospects. This can positively influence investor sentiment and potentially lead to an increase in stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100